Abstract:λ lncRNA‐modulated ceRNA networks may present a promising strategy for identifying candidate biomarkers in multiple types of human cancers λ VPS9D1‐AS1 and miR‐449a may serve as a potential therapeutic target in PCa. λ The findings in this study provide a better understanding of the ceRNA network involved in the prognosis of PCa and lay a solid foundation for improving PCa diagnosis and treatment. Despite advancements in cancer research, the prognostic implications of competing endogenous RNA (ceRNA) networks in prostate cancer (PCa) remain incompletely understood. This study aimed to elucidate the prognostic relevance of ceRNA networks in PCa, utilizing a comprehensive bioinformatics approach alongside experimental validation. After searching The Cancer Genome Atlas (TCGA) database, RNA sequencing (RNA‐Seq) data were extracted to identify differentially expressed RNAs (DERs) between 491 PCa samples and 51 normal prostate tissues, following which a comprehensive bioinformatics strategy was implemented to construct a ceRNA network. An optimal prognostic signature comprising these DERs was then established and validated using TCGA data. In addition, functional validation was performed through RNA pull‐down, dual‐luciferase reporter assays, quantitative real‐time PCR, and western blot analysis conducted in PC‐3 and DU145 cell lines, thereby complementing the bioinformatics analysis. A total of 613 DERs, comprising 103 long noncoding RNAs (lncRNAs), 60 microRNAs (miRNAs), and 450 messenger RNAs (mRNAs), were identified and utilized in constructing a ceRNA network, which encompassed 23 lncRNAs, 9 miRNAs, and 52 mRNAs. An optimal prognostic signature was established, including VPS9D1 antisense RNA 1 (VPS9D1‐AS1), miR‐449a, cyclin‐dependent kinase 5 regulatory subunit 1 (CDK5R1), targeting protein for Xklp2 (TPX2), solute carrier family 7 member 11 (SLC7A11), copine7 (CPNE7), and maternal embryonic leucine zipper kinase (MELK), yielding area under the curve (AUC) values exceeding 0.8 across training, validation, and entire datasets. Our experiments results revealed an interaction between lncRNA TRHDE antisense RNA 1 (TRHDE‐AS1) and miR‐449a and that miR‐449a could target the ADAM metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS5) mRNA. Knockdown of miR‐449a significantly impeded cell proliferation, G1/S transition, migration and invasion, and promoted apoptosis in PC‐3 and DU145 cells. Furthermore, knockdown of miR‐449a notably downregulated protein expression of CDK4, cyclin D1, N‐cadherin and vimentin, while upregulating protein expression of cleaved caspase‐3 and E‐cadherin. This study contributes to a deeper understanding of the prognostic‐linked ceRNA network in PCa, providing fundamental insights that could improve diagnostic and therapeutic approaches for PCa management.

Identification of androgen-responsive lncRNAs as diagnostic and prognostic markers for prostate cancer.

Identification of androgen response‐related lncRNAs in prostate cancer

Characterization and Validation of Long Noncoding RNAs As New Candidates in Prostate Cancer

Expression of lncRNA PCGEM1 and AR co-localization in prostate cancer and tis signiifcance

Identification of Specific Long Non-Coding Ribonucleic Acid Signatures and Regulatory Networks in Prostate Cancer in Fine-Needle Aspiration Biopsies

Androgen-responsive lncRNA LINC00304 promotes cell cycle and proliferation via regulating CCNA1.

Comprehensive Characterization of Androgen-Responsive Lncrnas Mediated Regulatory Network in Hormone-Related Cancers.

Discovery and Characterization of Long Intergenic Non-Coding RNAs (lincrna) Module Biomarkers in Prostate Cancer: an Integrative Analysis of RNA-Seq Data

Upregulation Of Long Noncoding Rna Loc440040 Promotes Tumor Progression And Predicts Poor Prognosis In Patients With Prostate Cancer

In Silico Bioinformatics Analysis on the Role of Long Non-Coding RNAs as Drivers and Gatekeepers of Androgen-Independent Prostate Cancer Using LNCaP and PC-3 Cells

The prognostic value of long noncoding RNAs in prostate cancer: a systematic review and meta-analysis.

Linc00963: A Novel, Long Non-Coding Rna Involved In The Transition Of Prostate Cancer From Androgen-Dependence To Androgen-Independence

Identification of novel biomarkers in prostate cancer diagnosis and prognosis

Identification and validation of the TRHDE‐AS1/hsa‐miR‐449a/ADAMTS5 axis as a novel prognostic biomarker in prostate cancer

Identification of Long Noncoding RNAs That Exert Transcriptional Regulation by Forming RNA–DNA Triplexes in Prostate Cancer

Specific expression of lncRNA RP13-650J16.1 and TCONS_00023979 in prostate cancer.

Utilizing Liquid-liquid phase separation-related lncRNAs to predict the prognosis and treatment response of PCa

[Bioinformatic analysis of immune-related lncRNA based on TCGA database in patients with prostate cancer]

A five-pseudouridylation-associated-LncRNA classifier for primary prostate cancer prognosis prediction

A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival

LINC00675 Activates Androgen Receptor Axis Signaling Pathway to Promote Castration-Resistant Prostate Cancer Progression